Expectations for Gilead’s Combination Data With Spring Bank
Insights - Spring Bank (SBPH) has been a frustrating position for us because the thesis has remained the same, yet the stock has traded down to $3, … Continue Reading
Read nowAuthor Archives: D Mero
Shionogi Taste Data Validates Selective P2X3 & Bellus
Insights - More data from Shionogi, Bellus’ competitor, was presented at European Respiratory Society (ERS) this weekend. Shionogi presented an abstract for their selective P2X3 antagonist, S-600918, and showed … Continue Reading
Read now
Bellus Uplists & Fennec’s Plan B for Self-Commercialization
Insights - Last week Bellus uplisted to the Nasdaq, trading under ticker BLU. To complete the uplisting, Bellus announced a 3.6:1 consolidation of common shares and a … Continue Reading
Read now
Adverum’s Phase 1 Disappoints on Visual Acuity & Inflammation
Insights - Adverum released preliminary Phase 1 data prior to the market opening. Data was rather vague and did not meet our expectations because it did not clearly place … Continue Reading
Premium
Market Overreacts to Amarin’s 3 Month Delay
Insights - What Happened?Amarin (AMRN) was down 20% in aftermarket trading yesterday upon announcing that the FDA will hold an advisory committee meeting (ADCOM) on November 14. The FDA … Continue Reading
Read nowExpectations for Adverum’s WetAMD Phase 1 Data in September
Insights - ADVM will present Phase 1 data in Wet AMD this September We set expectations for September data by looking at competitor RGNX Phase 1 data … Continue Reading
PremiumKey Takeaways From Bellus’ Chronic Cough KOL Call
Insights - Bellus hosted their Chronic Cough KOL meeting this morning. It was paneled by: Jacky Smith: lead investigator of Bellus Phase 2 trials Denis Garceau: Bellus VP of … Continue Reading
Read now